Mirugen – Unlocking the Power of Retina Regeneration
Mirugen – Unlocking the Power of Retina Regeneration
Search
Search results
SB-007 update: dose-expansion portion of SpliceBio’s phase 1/2 trial underway with first participant dosed at Oxford
SpliceBio has begun the dose-expansion portion of their phase 1/2 clinical trial of SB-007, a dual adeno-associated viral vector gene therapy for Stargardt disease.
Artificial vision
There are about 125 million rod and cone cells within the retina that act as the eye's light receptors.
Giving in memory
Celebrate the life of your loved one, by donating in their memory and help us fund more research and support, now.
Volunteer for us
Volunteers are highly valued members of the Retina UK team and essential to our ability to achieve our vision of a world where all those affected by inherited retinal conditions are able to live a fulfilling life.
Talk & support service
Our Retina UK Talk & support service (formerly Telephone Befriending Service) links people who may be feeling isolated or lonely with a trained volunteer for regular contact.
Funding paves the way for achromatopsia
A research project funded by Retina UK helped pave the way to a new gene therapy that has recently produced encouraging results in two young people with achromatopsia, a condition that causes complete colour-blindness and poor overall vision from birth.
How we can work together
We can provide all the support your organisation needs to work with us; from ideas to practical support and materials. The Retina UK team will help your contribution be as fun and rewarding as possible.
Trusts and Foundations
Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.
Look Forward – Autumn 2025 – Issue 187
Since the publication of this newsletter our founder and honorary president Lynda Cantor MBE has passed away. We are all deeply saddened by this news.